- Strategic partnership with ParagonCare (ASX:PGC), a leading Australian healthcare company
- Demonstration of AVIEW LCS Plus, an optimized lung cancer screening product, at ALCC 2025 on the 19th
- Consulting based on experience from securing lung cancer screening contracts in Italy, five European countries, etc.
CorelineSoft, led by CEO Kim Jin-guk, a medical AI specialist, has given the green light to enter the Australian market, one of the three largest medical device markets in Asia and the Atlantic region.
CorelineSoft, recently established a partnership with ParagonCare (ASX:PGC), a comprehensive healthcare company leading the Australian market. ParagonCare Group is a major Australian healthcare company with an annual sales revenue of approximately 3 trillion won, supplying over 100 brands of diagnostic and therapeutic equipment, solutions, and consumables to the medical market. It has subsidiaries in New Zealand, South Korea, Thailand, China, Vietnam, and the Philippines.
This partnership focuses on accelerating the adoption of products in major hospitals, based on the Australian National Lung Cancer Screening program starting this July, and enhancing the quality of healthcare services in Australia through AI-based workflow management. The two companies plan to set new standards in the Australian healthcare system by combining ParagonCare's extensive distribution network with CorelineSoft's technological innovations.
n addition, they will participate in the Australian Lung Cancer Conference (ALCC 2025) on the 19th, providing specialized consulting tailored to Australia's screening environment. This conference will be attended by leading researchers, clinicians, and policymakers in the field of lung cancer in Australia, aimed at sharing the latest developments and current issues in lung cancer diagnosis, treatment, and prevention. CorelineSoft plans to demonstrate advanced products in collaboration with ParagonCare and provide expert consulting to maximize diagnostic accuracy and develop patient-specific treatment plans.
The AVIEW LCS Plus, which will be demonstrated at the conference, is a product already used in national lung cancer screening in several European countries. It is specially optimized for large-scale diagnostic programs, improving diagnostic accuracy and operational efficiency. It has been successfully supplied to national lung cancer screening projects like Germany’s HANSE, Italy’s RISP, and 4ITRL involving five European countries, significantly accelerating the adoption of AI-based screening processes. Following the success of HANSE, Germany has recommended AI as the primary diagnostic tool for lung cancer screening, with similar movements noted in major European countries, including France.
Seo Jung-hyuk, Director of Overseas Business at CorelineSoft, stated, "Our collaboration with ParagonCare is expected to be a significant turning point in the Australian market. By integrating AI technology with healthcare services, we aim to provide better lung cancer screening solutions across Australia and contribute to raising awareness about the importance of early lung cancer detection."
